Perampanel as First Add-On Therapy in Patients with Focal-Onset Seizures in the FAME Trial: Post hoc Analyses of Efficacy and Safety Related to Maintenance Dose and Background Antiepileptic Drug Therapy

BACKGROUND AND PURPOSE: FAME (Fycompa(®) as first Add-on to Monotherapy in patients with Epilepsy; NCT02726074), a previously reported single-arm, phase IV study, showed that perampanel improved seizure control as first add-on to failed anti-seizure medication (ASM) monotherapy in 85 South Korean pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Ji Hyun, Kim, Dong Wook, Lee, Sang Kun, Seo, Dae-Won, Lee, Ji Woong, Kim, Min Young, Lee, Sang Ahm
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Epilepsy Society 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9289376/
https://www.ncbi.nlm.nih.gov/pubmed/35910326
http://dx.doi.org/10.14581/jer.22003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9289376/
https://www.ncbi.nlm.nih.gov/pubmed/35910326
http://dx.doi.org/10.14581/jer.22003

Ejemplares similares